Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting.<br>LINK TO FULL TRANSCRIPT

GU Cancer Highlights From ASCO26: PROTEUS, TALAPRO-3, and RAMPART

ASCO Daily News

Every smile on a child's face. Every moment spent enjoying something beautiful. Every meal shared with loved ones matters for your cancer patients. Biomarker testing can help in the fight for more moments like these. That's why Pfizer built a biomarker resource for HCPs that brings guidelines and insights together in one place. Every biomarker test, every insight, every opportunity matters. Get started at cancer.fizer.com.

Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm a professor of medicine and medical oncology at the Huntsman Cancer Institute, University of Utah, and editor in chief of the ASCO Daily News. I'm delighted to be joined by Dr. Jeannie Aragon-Cheng, a GU medical oncologist and the clinical program director of GU Cancers at the Innova

Shar Cancer Institute in Virginia. Today, we will be discussing some high-impact abstracts in GU oncology that were presented at the 2026 ASCO annual meeting. Our full disclosures are available in the transcript of this episode. So Jeannie, it's great to have you on the podcast today.

Thank you so much, Neeraj. It's a pleasure to be here. So ASCO 2026 featured some fascinating advances across GU cancers, and I'm very excited to dive into them with you today. So let's begin with the prostate abstracts. So first of all, Neeraj, congratulations on presenting the impressive results from the Phase 3 TALA Pro 3 trial, a simultaneous publication in the New England Journal of Medicine.

So can you give our listeners an overview of the TALA Pro 3 trial, its rationale, design, key findings that were presented? Of course. Thank you, Jeannie. TALA Pro 3 is a global Phase 3 trial designed to address an important unmet need in metastatic castration-sensitive prostate cancer...

GU Cancer Highlights From ASCO26: PROTEUS, TALAPRO-3, and RAMPART

Read the full transcript

The candid version is on a podcast,
not the earnings call.

GU Cancer Highlights From ASCO26: PROTEUS, TALAPRO-3, and RAMPART

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.